熱門資訊> 正文
Auria Pharmaceuticals收购Kezar Life Sciences
2026-03-30 22:06
- Aurinia Pharmaceuticals (AUPH) is acquiring Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one contingent value right.
- The CVR gives the shareholder the right to receive: (i) potential payments relating to the ongoing clinical development of zetomipzomib; (ii) certain proceeds relating to Kezar’s collaboration with Everest Medicines and Kezar’s sale of its Sec61‑based discovery and development program to Enodia Therapeutics; and (iii) 100% of Kezar’s closing net cash exceeding $50M.
- Zetomipzomib is a potential first-in-class immunoproteasome inhibitor in phase 2 autoimmune hepatitis. In a phase 2 trial, zetomipzomib showed durable steroid-sparing remissions. The candidate is also under investigation for lupus nephritis and systemic lupus erythematosus.
More on Aurinia Pharma, Kezar Life Sciences
- Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
- Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)
- Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
- Aurinia Pharmaceuticals appoints Kevin Tang as CEO
- Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
